BIOtechNOW News & Videos - Business Development Sponsor Logo

Business Development

Videos

One-on-One Partnering broke all records - more than 25,500 partnering meetings took place in Chicago. Joe Colangelo, Director of Business Development, reviews.
One-on-One Partnering Breaks All Industry Records
Anthony Raeside, Head of Research, Evaluate Pharma
Chris Morrison, EBI, interviews Glen Giovannetti, Ernst & Young
Briggs Morrison, EVP of Global Medicine Development, AstraZeneca
Peter Pellerito, State Policy and University Relations, BIO
Jim Greenwood, President and CEO, BIO
Small Companies Thinking Big: China Tactical Strategies
25,000+ One-on-One Partnering meetings are taking place in Chicago
Bill Hearl, President & CEO - Immunomic Therapeutics
Dave Mead, Director, Business Development, Novozymes Biopharma
Bill Hagstrom
Steven Damon. President & Founder, 4P Therapeutics
Paul Hastings, CEO, OncoMed Pharmaceuticals
Dr. Claudia Roth, President, Vetter Development Service USA
Dr. Trevor Mundel, President Global Health, Gates Foundation
William Waddill, CFO, Oncomed Pharmaceuticals
Governor Jay Nixon, Missouri
Patrick Lucy, Vice President of Business Development, Pfenex

Articles from BioTechNow

Venture Capital Trends

Posted: 4/24/23013 By: BIOtechNOW Editor


With industry data and numbers, results are always a mixed bag, says David Thomas, BIO’s Director of Industry Research & Analysis – and the latest on venture capital trends is no exception. In the U.S., biotech VC funding is flat, and start-up money is drying up. According to the National Venture Capital Association (NCVA), U.S. VC funding for biotech fell to $4.1 billion in 2012 (figure 1). This 17% drop was greater than the 10% decrease in funding seen across all sectors. The number of biotech financings... 

Read More >

Vote in the 2014 Buzz of BIO Contest!

Publish Date: 4/15/2014, Created By: Jessica Torres


The BIO International Convention is all about raising your profile, making connections, and moving your business forward. One of the more creative and fun ways for companies to accomplish these goals is the annual Buzz of BIO contest. This is an online voting contest for the industry to cast their pick for this year’s most creative biotech company. Prizes This year, there are two categories: Pipelines of Promise, and Technologies of Tomorrow. One company from each of ...

Read More >

BIO Convention Post-Con, Plus a Look Ahead

Publish Date: 5/21/2013, Created By: Sondra Behan


Last month, the biopharma community gathered for the industry’s largest event, the BIO International Convention. We hope the event was successful for everyone who attended. We know it was a busy time for folks, especially based on the numbers from the Partnering System! Here is a quick recap: BIO One-on-One Partnering Stats for BIO2013 A total of 25,537 One-on-One Partnering meetings were scheduled at the event, officially beating last year’s record! Partnering Meeting Requests increased ...

Read More >

State of the Biotech Industry: Burrill’s Biotech 2013 Report

Publish Date: 4/24/2013, Created By: BIOtechNOW Editor


To open his Super Session at the 2013 BIO International Convention, G. Steven Burrill, CEO of Burrill & Company, injected some humor for the hundreds of attendees in the audience, saying after 45 years in the biotech industry, 27 years authoring the Burrill State-of-the-Industry Report and 20 years of presenting the report at Convention, he was determined to get through 228 slides in 90 minutes. And, he delivered, providing a comprehensive snapshot of the industry ...

Read More >

Managed Entry Trumps Risk Sharing

Publish Date: 4/24/2013, Created By: BIOtechNOW Editor


Since 2000, pharmaceu-tical and biotech companies have engaged in agreements with government and private payers across the world to gain market access for their innovative drugs despite struggles to qualify for formal reimbursement criteria, such as the cost effectiveness threshold from NICE in the UK. These agreements, usually referred to as “risk sharing” agreements, have had a wide variety of structures but usually do not involve any sharing of risk, as the name misleadingly suggests. ...

Read More >

Ernst & Young’s Beyond Borders: Matters of Evidence

Publish Date: 4/24/2013, Created By: BIOtechNOW Editor


Hundreds of attendees turned out to glean insights from findings outlined in Ernst & Young LLP’s (EY) 27th annual report on the biotechnology industry – Beyond borders: matters of evidence – officially launched at Tuesday morning’s Super Session at the 2013 BIO International Convention. The report was presented by Glen Giovannetti and Gautam Jaggi of EY’s Global Life Sciences Center, and the Super Session featured a panel of industry leaders, including: Brian Edelman, VP, Corporate ...

Read More >

Results from the BIO Convention 2013 Meeting Analysis of Therapeutic In/Out Licensors

Publish Date: 4/24/2013, Created By: David Thomas, CFA


BIO’s results from the BIO 2013 Convention 1×1 meeting analysis conducted to identify trends and intentions of therapeutic in-licensors and out-licensors were released today. The analysis looked at the meeting activity of 180 in-licensors attending the Chicago conference in terms of what therapeutic areas and stages of development were in highest demand. Of the 804 drug R&D companies, companies in Phase I/Rare Disease came out ahead as a group, with an average of >17 meetings/company. This was followed by Phase ...

Read More >

Venture Capital Trends

Publish Date: 4/24/2013, Created By: BIOtechNOW Editor


With industry data and numbers, results are always a mixed bag, says David Thomas, BIO’s Director of Industry Research & Analysis – and the latest on venture capital trends is no exception. In the U.S., biotech VC funding is flat, and start-up money is drying up. According to the National Venture Capital Association (NCVA), U.S. VC funding for biotech fell to $4.1 billion in 2012 (figure 1). This 17% drop was greater than the 10% ...

Read More >

Finding Biotech in the Silicon Prairie

Publish Date: 4/23/2013, Created By: BIOtechNOW Editor


The Silicon Prairie is about more than technology companies and Internet start-ups. In fact, the biotech industry in Illinois employs nearly 80,000 people, according to a recent analysis by Battelle, and their salaries are double the salary of the average private sector worker in the state. As biotech executives from across the globe descend upon McCormick Place this week for the annual BIO International Convention, they will have an opportunity to see that the Chicago ...

Read More >

BIO One-On-One Partnering Kicks Off!

Publish Date: 4/23/2013, Created By: Jessica Torres


Partnering kicked off this today at the Business Forum at the 2013 BIO International Convention, and the numbers so far show that we have a strong week ahead of us. Over 130,000 partnering meeting requests have been requested Almost 22,000 meetings are already scheduled 4,900 of those meetings are exhibitor partnering meetings For a more in-depth look at the types of companies being represented at and stats on how many partnering meetings are taking place, check out this interview with ...

Read More >

Opening Up Innovation

Publish Date: 4/23/2013, Created By: BIOtechNOW Editor


Open Innovation has become a major theme in the life sciences over the last couple of years. Most of the attention has focused on initiatives where big pharma offers access to non-core assets to outside researchers in the hope that they will develop them successfully or form collaborations. In Sweden, AstraZeneca have followed this path, but interest in the concept has spread further down the discovery chain, generating creative initiatives from universities, tech transfer organizations, ...

Read More >